Monthly Archives: October 2013

Biotech IPOs: The Exit Challenge As Lockups Expire
October 31, 2013

Six months ago the biotech industry was on the verge of a sizzling season for IPOs, and since then, on average, we’ve seen one new biotech IPO per week.  Valuations of many of these offerings have been impressive, and this


Blogging on Biotech: Reflections And A ‘Best of’ List
October 17, 2013

For the past 2.5 years I’ve been experimenting with this blog, covering topics about biotech startups, the pharma industry, and venture capital – so I thought it would be a good time for reflection. In my first blog post in


VCs: Adding or Subtracting Value to Biotech Startups?
October 14, 2013

Last month legendary investor Vinod Khosla commented that 95% of VCs add “zero value” and 80% probably “add negative value” in how they advise startup companies in their portfolio.  This is a stunning indictment of the VCs that Khosla has

1 Comment

Insider Participation Drops As Biotech Offerings Up
October 6, 2013

As you might expect given the strong IPO market, biotech venture investors are doing less of the heavy lifting in support of their portfolio companies during this receptive climate than in the past few years. Biotech insider participation was the

Leave a comment